Hospira (HSP) Relaunches Chemo Medication Oxaliplatin Injection; Generic Form of Eloxatin (SNY)
Tweet Send to a FriendGet Alerts HSP Hot Sheet
Down)
Trade HSP Now!
Hospira, Inc. (NYSE: HSP), announced today the U.S. re-launch of oxaliplatin injection, Hospira's generic version of Sanofi's (NYSE: SNY) chemotherapy medication Eloxatin.
Sales of Eloxatin last year in the United States were approximately $1.5 billion.
Hospira originally launched oxaliplatin injection in August 2009 following a favorable ruling in patent litigation with Sanofi. Hospira settled the litigation with Sanofi in 2010 under an agreement which called for the eventual suspension of Hospira's sales at the end of June 2010, with the right to re-launch the product well in advance of patent expiry.
Oxaliplatin injection is a widely used oncology agent typically used to help treat colon and colorectal cancer. Hospira will initially offer oxaliplatin injection in 50 mg and 100 mg single-use vials. Hospira's oxaliplatin is a solution form of the product.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Sales of Eloxatin last year in the United States were approximately $1.5 billion.
Hospira originally launched oxaliplatin injection in August 2009 following a favorable ruling in patent litigation with Sanofi. Hospira settled the litigation with Sanofi in 2010 under an agreement which called for the eventual suspension of Hospira's sales at the end of June 2010, with the right to re-launch the product well in advance of patent expiry.
Oxaliplatin injection is a widely used oncology agent typically used to help treat colon and colorectal cancer. Hospira will initially offer oxaliplatin injection in 50 mg and 100 mg single-use vials. Hospira's oxaliplatin is a solution form of the product.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Sanofi (SNY) Reports JAKARTA Met Primary Endpoint in Both Groups
- Zoetis (ZTS) Reveise FDA Approval of APOQUEL
- Oramed Pharma (ORMP) OK'd by FDA for ORMD-0801 IND
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
